Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Items 701–800 of 1,000
Ling, X., Liu, S., Yang, Y., Dong, Q., Marcaurelle, L. A., Huang, W., Ding, Y., Wang, X., & Lu, X. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00068 · Cited by 11
Yao, H., Wang, X., Chi, J., Chen, H., Liu, Y., Jiayi, Y., Yu, J., Ruan, Y., Xiang, X., Pi, J., et al. (2024) · Molecules · doi:10.3390/molecules29050964 · Cited by 12
Enantioselective protein affinity selection mass spectrometry (E-ASMS)
Wang, X., Sun, J., Ahmad, S., Yang, D., Li, F., Chan, U. H., Zeng, H., Simoben, C. V., Green, S. R., Silva, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67403-2 · Cited by 18
Bhagath Kumar, P., Kotapati, K. V., Sapam, T. D., Sampath Kumar, R., Doucet, D. S., Retnakaran, A., Krell, P. J., Feng, Q., & Ampasala, D. R. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.03.037 · Cited by 11
Repair strategies for multiple sclerosis: challenges, achievements and perspectives
Stankoff, B., Jadasz, J. J., Hartung, H., Küry, P., Zalc, B., & Lubetzki, C. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000325 · Cited by 12
Baker, M. A., Schneider‐Futschik, E. K., Huang, J. X., Cooper, M. A., Li, J., & Velkov, T. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00700 · Cited by 11
Bandyopadhyay, D., Kreatsoulas, C., Brady, P. G., Boyer, J., He, Z., Scavello, G. S., Peryea, T., Jadhav, A., Nguyễn, Ð.-T., & Guha, R. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00243 · Cited by 11
Domain-adversarial multi-task framework for novel therapeutic property prediction of compounds
Xie, L., He, S., Zhang, Z., Lin, K., Bo, X., Yang, S. H., Feng, B., Wan, K., Yang, K., Yang, J., et al. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa063 · Cited by 11
Statistical models for identifying frequent hitters in high throughput screening
Goodwin, S., Shahtahmassebi, G., & Hanley, Q. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-74139-0 · Cited by 11
Vanderwall, D. E., Yuen, N., Al-Ansari, M. B., Bailey, J. M., Fram, D. M., Green, D. V. S., Pickett, S. D., Vitulli, G., Luengo, J. I., & Almenoff, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.001 · Cited by 11
Self-citationGupta, D. K., Xi, H., Liu, R., Hasan, A., & Feng, Z. (2015) · Neurodegenerative Diseases · doi:10.1159/000440845 · Cited by 11
Quantitative MALDI‐MS Binding Assays: An Alternative to Radiolabeling
Rossato, M., Miralles, G., M’Kadmi, C., Maingot, M., Amblard, M., Mouillac, B., Gagne, D., Martínez, J., Subra, G., Enjalbal, C., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201600447 · Cited by 11
Whittingham, H., & Ashenden, S. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820045-2.00006-4 · Cited by 13
Machine Learning-Driven Data Valuation for Optimizing High-Throughput Screening Pipelines
Hesse, J., Boldini, D., & Sieber, S. A. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01547 · Cited by 13
Astigarraga, M., Sánchez-Ruiz, A., & Colmenarejo, G. (2025) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2025.100127 · Cited by 18
Liu, Y., Zhang, P., Li, D., Che, C., & Jin, B. (2025) · Expert Systems with Applications · doi:10.1016/j.eswa.2025.127699 · Cited by 13
Multimodal Machine Learning Analysis of GaSe Molecular Beam Epitaxy Growth Conditions
Yu, M., Moses, I. A., Reinhart, W. F., & Law, S. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c02891 · Cited by 14
Müller, A. T., Hierl, M., Heer, D., Westwood, P., Hartz, P., Wörsdörfer, B., Krämer, C., Haap, W. J., Roth, D., & Reutlinger, M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00943 · Cited by 11
Kooij, R., Pol, V., Gan, J., van Doodewaerd, B. R., Sapmaz, A., Alonso, M. C., Fritz, G., Knobeloch, K., & Geurink, P. P. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202510941 · Cited by 10
Nazarova, A. L., Sadybekov, A., Sadybekov, A. A., Protopopov, M., Radchenko, D. S., Moroz, Y. S., Tarkhanova, O. O., & Katritch, V. (2026) · npj Drug Discovery. · doi:10.1038/s44386-026-00053-6 · Cited by 11
Design and application of synthetic human gut microbial communities
Kim, M. S., & Bisanz, J. E. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2575923 · Cited by 10
“Just as successful small-molecule or biological pharmaceuticals depend on mapping receptor‒ligand interactions and their downstream cascades, 156,157 microbiome therapeutics require the identification of specific organisms and their functional contributions to physiological, metabolic, and…”
Benabbou, A., Khibech, O., Draoui, Y., Bouhrim, M., Ziyat, H., Al-Zharani, M. M., Nasr, F. A., Qurtam, A. A., Abadi, S., Challioui, A., et al. (2026) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2026.109330 · Cited by 12
Chao, J. T., Roskelley, C. D., & Loewen, C. J. R. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04117-4 · Cited by 10
“For these reasons, deep learning techniques are well-suited for automating the analysis of high-content microscopy (HCM) data, in which high information content is captured for each sample [14]; or high-throughput microscopy data, in which multiple samples are imaged in rapid succession [15].”
Integrated “Generate, Make, and Test” for Formulated Products using Knowledge Graphs
Sunkle, S., Jain, D., Saxena, K., Patil, A., Singh, T., Rai, B., & Kulkarni, V. (2021) · Data Intelligence · doi:10.1162/dint_a_00096 · Cited by 10
“The concept of high-throughput (HT) screening has been around for more than five decades [22, 23, 24] and has been applied across wide range of domains like electrolytes [25], catalysts [26], and biomedical research [27].”
BackgroundWang, T., Shao, Z., Xiao, Y., Zhang, X., Chen, Y., Shi, B., Chen, S., Wang, Y., Peng, J., & Shang, X. (2021) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm52615.2021.9669479 · Cited by 11
HelixMO: Sample-Efficient Molecular Optimization in Scene-Sensitive Latent Space
Chen, Z., Fang, X., Hua, Z., Huang, Y., Wang, F., & Wu, H. (2022) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm55620.2022.9995561 · Cited by 11
“High-throughput screening (HTS) [1] through laboratory experiments and visual screening (VS) [2], [3] through in-silico experiments are usually involved in drug development.”
BackgroundMapping the Protein Kinome: Current Strategy and Future Direction
Hou, Z., & Liu, H. (2023) · Cells · doi:10.3390/cells12060925 · Cited by 11
“Some challenges limit the full potential of kinases as drug targets, including validating novel kinase targets [9], obtaining target selectivity to reduce off-targetmediated toxicity [10], and developing efficient compound screening technologies [11].”
BackgroundHardie, A., Cossins, B. P., Lovera, S., & Michel, J. (2023) · Communications Chemistry · doi:10.1038/s42004-023-00926-1 · Cited by 10
Liao, H.-X., Bando, K., Li, M., & Fujita, K. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02129 · Cited by 11
Kazakova, E., Lane, T. R., Jones, T., Puhl, A. C., Riabova, O., Makarov, V., & Ekins, S. (2023) · ACS Omega · doi:10.1021/acsomega.3c06106 · Cited by 10
A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
Niazi, S. K. (2023) · Pharmaceuticals · doi:10.3390/ph16111556 · Cited by 13
Tan, Y. Q., Sun, B., Zhang, X., Zhang, S., Guo, H., Basappa, B., Zhu, T., Sethi, G., Lobie, P. E., & Pandey, V. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06551-7 · Cited by 11
“…drug screening demonstrated that Trametinib synergizes with NCK in AsPC-1 and BxPC-3 cell line To explore the therapeutic potential of NCK-based synergistic combinations for the treatment of PDAC, high-throughput drug screening with the Cambridge Cancer Compound Library was utilized [38].”
Ciblage thérapeutique des récepteurs couplés aux protéines G
Sebag, J. A., & Pantel, J. (2012) · médecine/sciences · doi:10.1051/medsci/20122810012 · Cited by 10
“Premièrement, les composés chimiques à tester sont issus de chimiothèques de petites molécules représentant une large diversité chimique que possèdent les laboratoires pharmaceutiques, mais aussi désormais certains laboratoires académiques [13].”
BackgroundComputational Drug Target Screening through Protein Interaction Profiles
Vilar, S., Quezada, E., Uriarte, E., Costanzi, S., Borges, F., Viña, D., & Hripcsak, G. M. (2016) · Scientific Reports · doi:10.1038/srep36969 · Cited by 10
Nonlinear Dose–Response Modeling of High-Throughput Screening Data Using an Evolutionary Algorithm
Ma, J., Bair, E., & Motsinger‐Reif, A. A. (2020) · Dose-Response · doi:10.1177/1559325820926734 · Cited by 10
Bridging the Gap Between Nanotoxicological Data and the Critical Structure–Activity Relationships
Yan, X., Yue, T., Zhu, H., & Yan, B. (2022) · Springer eBooks · doi:10.1007/978-981-16-9116-4_7 · Cited by 10
Workman, P., & Collins, I. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00001-2 · Cited by 10
The conformational musings of a medicinal chemist
Finch, H. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.016 · Cited by 10
Improving Classical Substructure-Based Virtual Screening to Handle Extrapolation Challenges
Biniashvili, T., Schreiber, E., & Kliger, Y. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200472s · Cited by 10
Non-stoichiometric inhibition in integrated lead finding – a literature review
Klumpp, M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1128892 · Cited by 11
“As high-throughput screening (HTS) [1] continues to mature,[2] the need to critically examine raw, primary”
BackgroundInfluentialDrug Screening to Treat Early-Onset Eye Diseases: Can Zebrafish Expedite the Discovery?
Zhang, L., Chong, L., Cho, J. Y., Liao, P., Shen, F., & Leung, Y. F. (2012) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0b013e31827a9969 · Cited by 12
“Large libraries of tens to hundreds of thousands of chemicals are applied to the testing system.(5) A number of assays can be done to reveal and determine the effects of a drug on protein subcellular localization, protein-protein interaction, and signal transduction.”
BackgroundJo, A., Jung, J., Kim, E., & Park, S. B. (2016) · Chemical Communications · doi:10.1039/c6cc02587k · Cited by 10
Bhat, S. M., Mudgal, P. P., Sudheesh, N. P., & Arunkumar, G. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1595591 · Cited by 10
“High-throughput assays speed up the identification of potentially active substances, from large compound libraries comprised of small molecules to complex natural products [99].”
BackgroundWang, Y., Xiao, L., Wu, P. C., Chen, Y. K., Lo, S. J., Hu, S. C., Chen, Y. H., Chiu, C. C.-C., & Yuan, S. F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113713 · Cited by 10
Ligand Discovery: High-Throughput Binding: Fluorescence Polarization (Anisotropy)
Holdgate, G. A., & HEMSLEY, P. E. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1197-5_10 · Cited by 10
Zhang, L., Domeniconi, G., Yang, C.-C., Kang, S.-G., Zhou, R., & Cong, G. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04214-4 · Cited by 10
de Rond, T., Gao, J., Zargar, A., de Raad, M., Cunha, J., Northen, T. R., & Keasling, J. D. (2019) · Angewandte Chemie · doi:10.1002/ange.201901782 · Cited by 10
Zhang, X., Götte, M., Ibig-Rehm, Y., Schuffenhauer, A., Kamke, M., Beisner, D. R., Guerini, D., Siebert, D., Bonamy, G. M. C., Gabriel, D., et al. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217719834 · Cited by 10
“High-throughput screening is a productive approach to discover low-molecular-weight modulators of diverse biological targets and phenotypes.(10) In particular, advances in the development of image-based high-content screening (HCS) technologies have opened new avenues for screening campaigns on intracellular targets.”
BackgroundIn Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development
Lindner, J. R., & Morello, M. (2024) · Circulation · doi:10.1161/circulationaha.124.066522 · Cited by 10
AntiviralDB: an expert-curated database of antiviral agents against human infectious diseases
Huang, J., Song, Q., Zhang, P., Deng, L., Gao, F., Deng, Y., Król, E., Růžek, D., Khouri, R., Clercq, E. D., et al. (2025) · mBio · doi:10.1128/mbio.02013-25 · Cited by 9
van der Nol, E., Haupt, N., Gao, Q., Smit, B. A. M., Hoffmann, M., Engler, M. S., Ludwig, M., McKenna, S. M., Mata, J. M., Béquignon, O. J. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65282-1 · Cited by 9
Koyama, T., Tsumura, H., Okita, R., Yamazaki, K., Hasegawa, A., Imamura, K., Kato, T., Iwata, H., Kojima, R., Inoue, H., et al. (2026) · Journal of Cheminformatics · doi:10.1186/s13321-026-01155-z · Cited by 9
“Since the experimental validation of this space is time-consuming and costly, computational methods provide a promising approach for predicting CPIs [3].”
Maekawa, R., Hattori, K., Kirisako, H., Iwamoto, Y., Matsuo, M., Kawasaki, F., Yoneshiro, T., Sakai, J., & Ota, S. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6c00142 · Cited by 9
Rawson, S., McPhillie, M. J., Johnson, R. M., Fishwick, C. W. G., & Muench, S. P. (2017) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798317004077 · Cited by 9
“Despite the low probability of ISSN 2059-7983 identifying a hit, this approach has been successful in numerous drug-discovery programs (Macarron et al., 2011), including those for the antiretroviral inhibitor maraviroc and the protease inhibitor tipranavir, which are used to treat HIV infection,…”
BackgroundPhotoredox-catalysed hydroaminoalkylation of on-DNA N -arylamines
Mahdavi‐Amiri, Y., Hu, M. S. J., Frias, N., Movahedi, M., Csakai, A., Marcaurelle, L. A., & Hili, R. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob01956f · Cited by 9
Yang, T., Li, H., Kang, Y., & Li, Z. (2024) · Biomolecules · doi:10.3390/biom14081039 · Cited by 9
“Given the high cost and unsatisfactory efficiency of pharmaceutical research and clinical trials due to the large number of drug combinations, identifying synergistic effects between drugs remains a challenging task [11].”
BackgroundNovel drug discovery strategies for chronic obstructive pulmonary disease: the latest developments
Calzetta, L., Pistocchini, E., Gholamalishahi, S., Grugni, L., Cazzola, M., & Rogliani, P. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2490251 · Cited by 9
“These partnerships aim to enhance preclinical strategies, ensuring the identification of robust drug candidates that can successfully transition from laboratory research to clinical environments [23–26].”
Improving Activity Prediction of Adenosine A2B Receptor Antagonists by Nonlinear Models
Ghasemi, F., Mehri, A., Peña-García, J. J., den-Haan, H., Pérez, A., Fassihi, A., & Pérez‐Sánchez, H. (2015) · Lecture notes in computer science · doi:10.1007/978-3-319-16480-9_61 · Cited by 9
NMR screening and studies of target – ligand interactions
Polshakov, V. I., Batuev, E. A., & Mantsyzov, A. B. (2018) · Russian Chemical Reviews · doi:10.1070/rcr4836 · Cited by 9
Accurate Hit Estimation for Iterative Screening Using Venn–ABERS Predictors
Buendía, R., Kogej, T., Engkvist, O., Carlsson, L., Linusson, H., Johansson, U., Toccaceli, P., & Ahlberg, E. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00724 · Cited by 10
A Novel Sulfonyl-Based Small Molecule Exhibiting Anti-cancer Properties
El-Kadiry, A. E.-H., Abusarah, J., Cui, Y., El-Hachem, N., Hammond-Martel, I., Würtele, H., Thomas, S. C., Ahmadi, M., Balood, M., Talbot, S., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00237 · Cited by 9
Zhu, H., Cai, Y., Ma, S., Futamura, Y., Li, J., Zhong, W., Zhang, X., Osada, H., & Zou, H. (2021) · ChemSusChem · doi:10.1002/cssc.202101868 · Cited by 9
Human Serum Alters the Metabolism and Antibiotic Susceptibility of Staphylococcus aureus
Somerville, G. A., Parrett, A., Reed, J. M., Gardner, S. G., Morton, M., & Powers, R. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00073 · Cited by 9
Cell painting transfer increases screening hit rate
Cohen, E., Corbé, M., Franco, C. A., Vasconcelos, F. F., Perez, F., Nery, E. D., Bollot, G., & Genovesio, A. (2023) · Biological Imaging · doi:10.1017/s2633903x23000077 · Cited by 10
“It consists of identifying active chemical compounds that interact with a preidentified target through automated parallelized experimental tests((1,2)).”
BackgroundLigand and Structure-Based Drug Design (LBDD and SBDD): Promising Approaches to Discover New Drugs
Nascimento, I. J. D. S., & de Moura, R. O. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815179934123010003 · Cited by 11
The allure of targets for novel drugs
Suckling, C. J. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00621b · Cited by 9
High‐throughput screening (HTS) for the identification of novel antiviral scaffolds
Jadhav, M. P. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.99 · Cited by 9
“This is a classical success story of the medicinal chemistry efforts required in lead optimization to turn an HTS hit into a therapeutic candidate.(17) Examples of other drugs are provided in Table 1.”
BackgroundVirtual Screening Strategies: A State of Art to Combat with Multiple Drug Resistance Strains
Khan, A. U. (2015) · MOJ Proteomics & Bioinformatics · doi:10.15406/mojpb.2015.02.00042 · Cited by 9
“However, to bring a new drug takes approximately 10-14 years to get approval of a single drug from FDA (Food and Drug Administration, USA) before it comes in the market with the expense of ~1 billion USD [15,16].”
BackgroundReview: Basics of Drug Development in Rheumatology
Mina‐Osorio, P. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39253 · Cited by 9
“This process usually involves high-throughput screening (HTS) (22) in which a large number of compounds are tested for their ability to bind to a target or alter its function, e.g., inhibition of the enzymatic activity of a kinase or the binding of a cytokine to its receptor(s) (23).”
BackgroundCell Line Macroarray: An Alternative High-Throughput Platform to Analyze hiPSC Lines
Spada, A., Baronchelli, S., Ottoboni, L., Ruffini, F., Martino, G., Convertino, N., Ntai, A., Steiner, T., Biunno, I., & Blasio, A. D. (2016) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155416673969 · Cited by 10
“Furthermore, to address these needs and guarantee the use of these cells in medical research and drug development, different culture strategies, more robust production, and cell-specific differentiation protocols need to be implemented.(3) Currently, reprogramming of human primary dermal fibroblasts is often performed…”
BackgroundLee, C., Bang, K., Hong, D., & Lee, H. M. (2019) · 대한금속재료학회지 · doi:10.3365/kjmm.2019.57.1.1 · Cited by 9
CSgator: an integrated web platform for compound set analysis
Park, S., Kwon, Y., Jung, H., Jang, S., Lee, H., & Kim, W. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0339-6 · Cited by 9
Application of Biotechnology in Producing Plant Bio-active Compounds
Pereira, G. C. (2019) · Springer eBooks · doi:10.1007/978-981-13-7438-8_3 · Cited by 11
Wang, R., Wang, J., Liu, Y., Zhang, X., & Liang, X. (2019) · RSC Advances · doi:10.1039/c9ra06466d · Cited by 9
Ji, X., Jin, C., Dong, X., Dixon, M. S., Williams, K. P., & Zheng, W. (2020) · Molecules · doi:10.3390/molecules25173933 · Cited by 9
“In a typical drug discovery project, a first-step may be to identify hits via high-throughput screening of compound libraries [1].”
BackgroundThunor: visualization and analysis of high-throughput dose–response datasets
Lubbock, A. L. R., Harris, L. A., Quaranta, V., Tyson, D. R., & Lopez, C. F. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab424 · Cited by 10
“High-throughput in vitro screens of large panels of chemical compounds against hundreds to thousands of cultured cell lines is a powerful and increasingly popular tool for probing complex intracellular networks and identifying druggable targets in hypothesis-driven biomedical research (13).”
BackgroundAguiar-Cervera, J., Delneri, D., & Severn, O. (2021) · Engineering Biology · doi:10.1049/enb2.12013 · Cited by 12
“HTS technologies have been employed in a multitude of research fields for more than 2 decades, being particularly prevalent in the pharmaceutical industry [17].”
BackgroundTsui, L. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.08.001 · Cited by 9
Hornig, J., & McGregor, A. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.922538 · Cited by 9
“In silico studies encompass numerous models that have been and are currently being used for identifying new herpesvirus target antigens and antiviral compounds [22].”
BackgroundHigh-Throughput Screening (HTS) Technology
Roy, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_73 · Cited by 14
Ong, W. J. G., Kirubakaran, P., & Karanicolas, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.04.556234 · Cited by 12
“techniques can be time consuming and costly [6], presenting a natural opportunity for contributions from complementary in silico techniques.”
Rationally design the ionic liquid-based absorbents for CO2 absorption using machine learning
Gao, J., Guo, Y., Yu, Y. S., Wang, Z., & Dong, K. (2025) · Separation and Purification Technology · doi:10.1016/j.seppur.2025.132613 · Cited by 8
High-throughput screening strategies for space-based radiation countermeasure discovery
Putt, K. S., Du, Y., Fu, H., & Zhang, Z. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.07.004 · Cited by 11
Huang, K., Morato, N. M., Feng, Y., & Cooks, R. G. (2023) · Angewandte Chemie · doi:10.1002/ange.202300956 · Cited by 8
Multifaceted nucleic acid probing with a rationally upgraded molecular rotor
Kha, T., Shi, Q., Pandya, N., & Zhu, R. (2024) · Chemical Science · doi:10.1039/d4sc00141a · Cited by 8
Tatkiewicz, W. I., Seras‐Franzoso, J., García‐Fruitós, E., Vázquez, E., Kyvik, A. R., Ventosa, N., Guasch, J., Villaverde, A., Veciana, J., & Ratera, I. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01085 · Cited by 8
A KNIME Workflow for Automated Structure Verification
Lumley, J. A., Sharman, G. J., Wilkin, T., Hirst, M., Cobas, C., & Goebel, M. G. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220907091 · Cited by 8
Borba, J. V. V. B., Silva, A. C., Lima, M. N. D. N., Mendonça, S. S., Furnham, N., Costa, F. T. M., & Andrade, C. H. (2020) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2020.10.006 · Cited by 8
Tang, C., Niu, Q., Cicka, D., Du, Y., Mo, X., & Fu, H. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100804 · Cited by 8
“The discovery of an increasing number of oncogenic PPIs has significantly expanded the therapeutic target space (Boettcher et al., 2018; Grzeskowiak et al., 2018; Ivanov et al., 2017a, 2017b; Li et al., 2017; Mo et al., 2017; Rusnak et al., 2018).”
BackgroundInfluentialAbdulhasan, M. A., Ruden, X. L., You, Y., Harris, S. M., Ruden, D. M., Awonuga, A. O., Alvero, A. B., Puscheck, E. E., & Rappolee, D. A. (2021) · Frontiers in Toxicology · doi:10.3389/ftox.2021.709747 · Cited by 8
“Cell-based HTS are an important part of drug discovery and helps in assessing the risk of drug and environmental compound exposure (Macarron et al., 2011).”
BackgroundDNA-encoded library screening on two validated enzymes of the peptidoglycan biosynthetic pathway
Proj, M., Bozovičar, K., Hrast, M., Frlan, R., & Gobec, S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128915 · Cited by 8
AI and Big Data for Drug Discovery
Kavidopoulou, A., Syrigos, K. N., Makrogkikas, S., Dlamini, Z., Hull, R., Marima, R. M., Skepu, A., Koumoulos, E. P., Bakas, G., Vamvakaris, I. N., et al. (2022) · Integrated science · doi:10.1007/978-3-031-11199-0_7 · Cited by 9
Accounting Artifacts in High-Throughput Toxicity Assays
Hsieh, J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6346-1_15 · Cited by 8
Logical Experimental Design and Execution in the Biomedical Sciences
Holder, D., & Marino, M. J. (2017) · Current Protocols in Pharmacology · doi:10.1002/cpph.20 · Cited by 9
Repurposing strategies on pyridazinone-based series by pharmacophore- and structure-driven screening
Floresta, G., Crocetti, L., Giovannoni, M. P., Biagini, P., & Cilibrizzi, A. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1760261 · Cited by 8
High-Throughput Mechanism of Inhibition
Davies, G. M., Semple, H., McCandless, M., Cairns, J., & Holdgate, G. A. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220983809 · Cited by 8
“10 Inhibition modality may be determined in two ways: (1) by analysis of the impact of the inhibitor concentration on the steady-state parameters of the enzymatic reaction, Km and Vmax, and (2) by analysis of the effect of substrate concentration on the measured IC50.”
Method19 F-Tagged metal binding pharmacophores for NMR screening of metalloenzymes
Prosser, K. E., Kohlbrand, A. J., Seo, H., Kalaj, M., & Cohen, S. M. (2021) · Chemical Communications · doi:10.1039/d1cc01231b · Cited by 8
Nanopore-Based Sensors for Ligand–Receptor Lead Optimization
Luan, B., Huynh, T., & Zhou, R. (2015) · The Journal of Physical Chemistry Letters · doi:10.1021/jz5025614 · Cited by 8
Wingfield, J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13983-6 · Cited by 8
Wang, T., Gautam, P., Rousu, J., & Aittokallio, T. A. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.11.001 · Cited by 10
“In phenotype-based drug discovery, high-throughput screening (HTS) is often used to profile the sensitivity or toxicity of hundreds of drug molecules across panels of cell lines or patient-derived samples to identify a few hit compounds with desired response profiles for further development [1,2].”
Background
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.